Estrogen as a Safe Therapeutic Adjunct in Reducing the Inflammatory Storm in Trauma Hemorrhagic Shock Patients. Issue 4 (October 2021)

• Record Type: Journal Article
• Authors: Gupta, Dablu Lal; Tiwari, Shrestha; Sinha, Tej Prakash; Soni, Kapil Dev; Galwankar, Sagar; Kumar, Subodh; Rao, D.N; Bhoi, Sanjeev
• Is Part Of: Shock. Volume 56:Issue 4(2021)
• Publication Date: 2021-10
• Subjects: Emergency department (ED) -- estrogen -- inflammation -- multiple organ failure -- sepsis -- trauma hemorrhagic shock (THS) -- Abbreviations -- ISS -- injury severity score -- MODS -- multiple organ dysfunction syndromes -- MOF -- multiple organ failure -- SI -- shock index -- SOFA -- sequential organ failure assessment assay -- THS -- trauma hemorrhagic shock; Shock -- Periodicals; Shock -- Periodicals; Choc (Pathologie) -- Périodiques; Shock; Periodicals; 616.0475
• DOI: 10.1097/SHK.0000000000001779
• Languages: English
• ISSNs: 1073-2322

Abstract

Abstract : ABSTRACT: Trauma is a major cause of death and disability throughout the world. It is a leading cause of death with or without sepsis in about 50% of patients. Limited therapeutic options are available besides definitive care with a mortality benefit. Preclinical studies have demonstrated the mortality benefit of estrogen in trauma hemorrhagic shock (THS). Based on encouraging results from preclinical studies, we hypothesized that early administration of estrogen in male THS patients may reduce the inflammatory storm, prevent sepsis-associated problems, and subsequently reduce mortality. The authors studied the safety of early administration of estrogen as a therapeutic adjunct in the emergency department (ED) and its effects on the inflammatory storm, prevention of sepsis, and mortality during the intensive care unit stay. Forty THS patients were recruited. THS patients were divided into experimental and placebo control groups based on the estrogen administration in the ED. Serum levels of cytokines and immune cells were measured at different time points on days 0, 3, 7, and 14 in both groups of THS patients. The experimental group received intravenous estrogen (25 mg) at a single time point in the ED beside standard of care as per advanced trauma life support guidelines. Patients did not develop any major or minor adverse events and showed favorable clinical outcomes in the experimental group. The levels of T regulatory cells, monocytes, and systemic cytokines significantly reduced and showed a balanced inflammatory response in THS patients who received estrogen. In conclusion, this preliminary study showed that intravenous estrogen therapy is safe and reduced the inflammatory insult due to trauma hemorrhagic shock. It may protect THS patients from sepsis-associated complications. Future clinical trials are required to study the efficacy and mechanistic pathway. Abstract : Supplemental Digital Content is available in the text